BRPI0811979A2 - Formulação para vacinas de meningite - Google Patents

Formulação para vacinas de meningite

Info

Publication number
BRPI0811979A2
BRPI0811979A2 BRPI0811979-1A2A BRPI0811979A BRPI0811979A2 BR PI0811979 A2 BRPI0811979 A2 BR PI0811979A2 BR PI0811979 A BRPI0811979 A BR PI0811979A BR PI0811979 A2 BRPI0811979 A2 BR PI0811979A2
Authority
BR
Brazil
Prior art keywords
formulation
meningitis vaccines
meningitis
vaccines
Prior art date
Application number
BRPI0811979-1A2A
Other languages
English (en)
Inventor
Mario Contorni
Paolo Costantino
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0811979A2 publication Critical patent/BRPI0811979A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0811979-1A2A 2007-06-04 2008-06-04 Formulação para vacinas de meningite BRPI0811979A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93323507P 2007-06-04 2007-06-04
PCT/IB2008/002121 WO2008149238A2 (en) 2007-06-04 2008-06-04 Formulation of meningitis vaccines

Publications (1)

Publication Number Publication Date
BRPI0811979A2 true BRPI0811979A2 (pt) 2014-10-21

Family

ID=40094241

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811979-1A2A BRPI0811979A2 (pt) 2007-06-04 2008-06-04 Formulação para vacinas de meningite

Country Status (13)

Country Link
US (1) US20100203137A1 (pt)
EP (1) EP2152302B1 (pt)
JP (1) JP5637848B2 (pt)
CN (1) CN101678094B (pt)
AU (2) AU2008259423A1 (pt)
BR (1) BRPI0811979A2 (pt)
CA (1) CA2688268A1 (pt)
ES (1) ES2555786T3 (pt)
IN (1) IN2009KN04098A (pt)
MX (1) MX2009013112A (pt)
NZ (1) NZ581367A (pt)
RU (1) RU2009149359A (pt)
WO (1) WO2008149238A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541361A (en) 1998-05-01 2008-04-30 Inst Genomic Research Neisseria meningitidis antigens and compositions relating to SEQ ID Nos:2916, 2918 and 2920
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
EP2275553B1 (en) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
BR0108711A (pt) 2000-02-28 2004-06-22 Chiron Spa Expressão heteróloga de proteìnas de neisseria
US20030180316A1 (en) * 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
NZ564606A (en) 2005-06-27 2010-10-29 Glaxosmithkline Biolog Sa Immunogenic composition comprising atleast two N. meningitidis capsular polysaccharides conjugated through a linker protein
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DK2200642T3 (da) * 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
JP2011524375A (ja) 2008-06-16 2011-09-01 アカデミア シニカ GloboHおよびSSEA3に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
WO2010109324A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CN101590225B (zh) * 2009-06-19 2012-02-15 长春长生生物科技股份有限公司 百白破、A+C群脑膜炎球菌-b型流感嗜血杆菌结合疫苗
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
RU2013131795A (ru) * 2010-12-10 2015-01-20 Мерк Шарп Энд Домэ Корп. Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций
US9283270B2 (en) * 2012-01-20 2016-03-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
RU2014140521A (ru) * 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2876138C (en) 2012-06-14 2023-09-19 Novartis Ag Vaccines for serogroup x meningococcus
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
DK3506935T3 (en) 2016-09-02 2024-04-02 Sanofi Pasteur Inc Neisseria meningitidis-vaccine
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
AU4841693A (en) 1992-08-31 1994-03-29 North American Vaccine, Inc. Vaccines against group c neisseria meningitidis
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20030180316A1 (en) 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
MXPA03006561A (es) 2001-01-23 2004-10-15 Aventis Pasteur Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
PT1777236T (pt) 2002-03-26 2017-02-13 Glaxosmithkline Biologicals Sa Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento
ES2411080T3 (es) * 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
PL1961426T3 (pl) 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN1709505B (zh) * 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
WO2007026249A2 (en) * 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
DK2200642T3 (da) * 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater

Also Published As

Publication number Publication date
ES2555786T3 (es) 2016-01-08
CN101678094B (zh) 2014-08-27
AU2008259423A1 (en) 2008-12-11
EP2152302A2 (en) 2010-02-17
WO2008149238A2 (en) 2008-12-11
AU2014204425B2 (en) 2015-10-29
JP5637848B2 (ja) 2014-12-10
NZ581367A (en) 2012-05-25
MX2009013112A (es) 2010-03-01
US20100203137A1 (en) 2010-08-12
JP2010529103A (ja) 2010-08-26
CA2688268A1 (en) 2008-12-11
EP2152302B1 (en) 2015-10-07
WO2008149238A3 (en) 2009-08-06
RU2009149359A (ru) 2011-07-20
CN101678094A (zh) 2010-03-24
IN2009KN04098A (pt) 2015-08-28
AU2014204425A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
BRPI0811979A2 (pt) Formulação para vacinas de meningite
DK2234600T3 (da) Antistofformulering
DK3072906T3 (da) Antistofformulering
DK2346495T4 (da) Farmaceutisk formulering 514
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
BRPI1006519A2 (pt) formulação de anticorpos
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0920240A2 (pt) formulação de adjuvante de combinação
BRPI0814252A2 (pt) Formulações de anticorpo
DE602008004859D1 (de) Positionsmessung
BRPI0814188A2 (pt) Formulações
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0906946A2 (pt) Vacinas baseadas em baculovírus
BRPI0818669A2 (pt) formulação para melhora da função gastrintestinal
BRPI0909492A2 (pt) dispositivo para produção de chocolate
BRPI0811732A2 (pt) Formulação de liberação prolongada de nevirapina
BRPI0912656A2 (pt) formulação farmacêutica sólida
BRPI0822199A2 (pt) Formulação herbicida
ES1067730Y (es) Dispositivo autoblocante para persiana
ES1065835Y (es) Caperuza para cetreria
ES1070237Y (es) "dispositivo antiseismos para la construccion"
ES1063735Y (es) Testero para persiana
ES1062971Y (es) Dispositivo de sujecion para muñecos
TH122323B (th) สูตรผสมวัคซีนชนิดใหม่
ES1065263Y (es) Captafaros para bionda

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Ipc: A61K 39/102 (2006.01), A61K 39/02 (2006.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]